Alzheimer's disease‐associated R47H TREM2 increases, but wild‐type TREM2 decreases, microglial phagocytosis of synaptosomes and neuronal loss
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Triggering receptor on myeloid cells 2 (TREM2) is an innate immune receptor, upregulated on the surface of microglia associated with amyloid plaques in Alzheimer's disease (AD). Individuals heterozygous for the R47H variant of TREM2 have greatly increased risk of developing AD. We examined the effects of wild‐type (WT), R47H and knock‐out (KO) of human TREM2 expression in three microglial cell systems. Addition of mouse BV‐2 microglia expressing R47H TREM2 to primary mouse neuronal cultures caused neuronal loss, not observed with WT TREM2. Neuronal loss was prevented by using annexin V to block exposed phosphatidylserine, an eat‐me signal and ligand of TREM2, suggesting loss was mediated by microglial phagocytosis of neurons exposing phosphatidylserine. Addition of human CHME‐3 microglia expressing R47H TREM2 to LUHMES neuronal‐like cells also caused loss compared to WT TREM2. Expression of R47H TREM2 in BV‐2 and CHME‐3 microglia increased their uptake of phosphatidylserine‐beads and synaptosomes versus WT TREM2. Human iPSC‐derived microglia with heterozygous R47H TREM2 had increased phagocytosis of synaptosomes vs common‐variant TREM2. Additionally, phosphatidylserine liposomes increased activation of human iPSC‐derived microglia expressing homozygous R47H TREM2 versus common‐variant TREM2. Finally, overexpression of TREM2 in CHME‐3 microglia caused increased expression of cystatin F, a cysteine protease inhibitor, and knock‐down of cystatin F increased CHME‐3 uptake of phosphatidylserine‐beads. Together, these data suggest that R47H TREM2 may increase AD risk by increasing phagocytosis of synapses and neurons via greater activation by phosphatidylserine and that WT TREM2 may decrease microglial phagocytosis of synapses and neurons via cystatin F.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Takahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046
Yuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.003 · Cited by 817
Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques
Condello, C., Yuan, P., Schain, A., & Grutzendler, J. (2015) · Nature Communications · doi:10.1038/ncomms7176 · Cited by 718
Filipello, F., Morini, R., Corradini, I., Zerbi, V., Canzi, A., Michalski, B., Erreni, M., Markicevic, M., Starvaggi-Cucuzza, C., Otero, K., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.016 · Cited by 695 · cited 2×
“TREM2 appears to also mediate microglial phagocytosis of synapses during development (Filipello et al., 2018), aging (Linnartz-Gerlach et al., 2019; Qu & Li, 2020) and AD (Sheng et al., 2019).”
BackgroundJay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142322 · Cited by 682 · cited 1×
“TREM2 expression has been shown to be upregulated in microglia that associate with amyloid plaques in Alzheimer's disease (AD) (Brendel et al., 2017; Giraldo et al., 2013; Jay et al., 2015; Yuan et al., 2016).”
BackgroundHaenseler, W., Sansom, S. N., Buchrieser, J., Newey, S. E., Moore, C. S., Nicholls, F. J., Chintawar, S., Schnell, C., Antel, J. P., Allen, N. D., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.05.017 · Cited by 593
Leyns, C. E. G., Ulrich, J. D., Finn, M. B., Stewart, F. R., Koscal, L. J., Remolina Serrano, J., Robinson, G. O., Anderson, E., Colonna, M., & Holtzman, D. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710311114 · Cited by 517 · cited 1×
“…in different rodent models of disease, loss of wild-type mTREM2 has been associated with either decreased (Wang et al., 2015) or increased phagocytosis (Schoch et al., 2021), and either decreased (Leyns et al., 2017) or increased synaptic and/or neuronal loss (Lee et al., 2021; Wang et al., 2015).”
BackgroundNew insights into the role of TREM2 in Alzheimer’s disease
Gratuze, M., Leyns, C. E. G., & Holtzman, D. M. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0298-9 · Cited by 489
RIPK1 mediates a disease-associated microglial response in Alzheimer’s disease
Ofengeim, D., Mazzitelli, S., Ito, Y., DeWitt, J. P., Mifflin, L., Zou, C., Das, S., Adiconis, X., Chen, H., Zhu, H., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714175114 · Cited by 395
Kawabori, M., Kacimi, R., Kauppinen, T., Calosing, C., Kim, J. Y., Hsieh, C. L., Nakamura, M. C., & Yenari, M. A. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2620-14.2015 · Cited by 375
Inhibition of Microglial Phagocytosis Is Sufficient To Prevent Inflammatory Neuronal Death
Neher, J. J., Neniskyte, U., Zhao, J.-W., Bal-Price, A., Tolkovsky, A. M., & Brown, G. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003600 · Cited by 373 · cited 4×
“Note that we did not show here that the neuronal loss was by phagocytosis, but have shown this previously (Neher et al., 2011; Neniskyte et al., 2011).”
BackgroundInfluentialSelf-citationMcQuade, A., Kang, Y. J., Hasselmann, J., Jairaman, A., Sotelo, A., Coburn, M., Shabestari, S. K., Chadarevian, J. P., Fote, G., Tu, C. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19227-5 · Cited by 361 · cited 1×
“In cultured microglia, Trem2 knockout has been found to reduce phagocytosis of synaptosomes after 24 h of incubation, but with no difference after 2 h (Filipello et al., 2018; McQuade et al., 2020).”
BackgroundWilgenburg, B. V., Browne, C., Vowles, J., & Cowley, S. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071098 · Cited by 353
Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology
Lee, S.-H., Meilandt, W. J., Xie, L., Gandham, V. D., Ngu, H., Barck, K. H., Rezzonico, M. G., Imperio, J., Lalehzadeh, G., Huntley, M. A., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.02.010 · Cited by 300 · cited 1×
“…in different rodent models of disease, loss of wild-type mTREM2 has been associated with either decreased (Wang et al., 2015) or increased phagocytosis (Schoch et al., 2021), and either decreased (Leyns et al., 2017) or increased synaptic and/or neuronal loss (Lee et al., 2021; Wang et al., 2015).”
BackgroundSong, W., Hooli, B., Mullin, K., Jin, S. C., Cella, M., Ulland, T. K., Wang, Y., Tanzi, R. E., & Colonna, M. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.004 · Cited by 297
Pattern Recognition by TREM-2: Binding of Anionic Ligands
Daws, M. R., Sullam, P. M., Niemi, E. C., Chen, T. T., Tchao, N. K., & Seaman, W. E. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.594 · Cited by 291 · cited 2×
“Triggering receptor on myeloid cells 2 (TREM2) is a receptor expressed on myeloid cells that triggers an innate immune response when activated (Daws et al., 2003; Deczkowska et al., 2020).”
BackgroundMicroglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau
Kang, S. S., Ebbert, M. T. W., Baker, K. E., Cook, C., Wang, X., Sens, J. P., Kocher, J.-P., Petrucelli, L., & Fryer, J. D. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180653 · Cited by 260 · cited 3×
“CST7 encodes cystatin F, an inhibitor of lysosomal cathepsins and microglial phagocytosis (Kang et al., 2018; Kos et al., 2018; Ofengeim et al., 2017), which is highly upregulated by TREM2 (Keren-Shaul et al., 2017).”
BackgroundThe Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease
Cheng-Hathaway, P. J., Reed-Geaghan, E. G., Jay, T. R., Casali, B. T., Bemiller, S. M., Puntambekar, S. S., von Saucken, V. E., Williams, R. Y., Karlo, J. C., Moutinho, M., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0262-8 · Cited by 252
Xiang, X., Piers, T. M., Wefers, B., Zhu, K., Mallach, A., Brunner, B., Kleinberger, G., Song, W., Colonna, M., Herms, J., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0280-6 · Cited by 170 · cited 4×
“Myeloid progenitors were further differentiated using IL-34, MCSF and TGF-β for 2 weeks, in addition to CX3CL1 and CD200 for the final 3 days (Piers et al., 2020; Xiang et al., 2018).”
BackgroundMethodInfluentialSelf-citationGarcia-Reitboeck, P., Phillips, A., Piers, T. M., Villegas-Llerena, C., Butler, M., Mallach, A., Rodrigues, C., Arber, C. E., Heslegrave, A., Zetterberg, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.094 · Cited by 162
Self-citationAD-linked R47H- TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation
Sayed, F. A., Kodama, L., Fan, L., Carling, G. K., Udeochu, J. C., Le, D., Li, Q., Zhou, L., Wong, M. Y., Horowitz, R., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe3947 · Cited by 155 · cited 2×
“More recently, Sayed et al. (2021) found that microglia from AD patients with R47H TREM2 were hyperactivated consistent with increased TREM2 signaling, and they generated mice expressing heterozygous R47H and found this exacerbated tauopathy, consistent with the toxic gain-of-function of R47H found…”
BackgroundResultSudom, A., Talreja, S., Danao, J., Bragg, E., Kegel, R., Min, X., Richardson, J., Zhang, Z., Sharkov, N., Marcora, E., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002352 · Cited by 149 · cited 3×
“For example, the binding of TREM2 to pure phosphatidylserine might be dominated by the charge interaction between the very negative liposomes and the positively-charged ligand-binding surface of TREM2, which is disrupted by R47H (Sudom et al., 2018).”
BackgroundGiraldo, M., Lopera, F., Siniard, A. L., Corneveaux, J. J., Schrauwen, I., Carvajal, J., Muñoz, C., Ramirez-Restrepo, M., Gaiteri, C., Myers, A. J., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.02.016 · Cited by 147
Piers, T. M., Cosker, K., Mallach, A., Johnson, G. T., Guerreiro, R., Hardy, J., & Pocock, J. M. (2020) · The FASEB Journal · doi:10.1096/fj.201902447r · Cited by 135 · cited 2×
“Myeloid progenitors were further differentiated using IL-34, MCSF and TGF-β for 2 weeks, in addition to CX3CL1 and CD200 for the final 3 days (Piers et al., 2020; Xiang et al., 2018).”
BackgroundMethodSelf-citationTREM2 triggers microglial density and age-related neuronal loss
Linnartz‐Gerlach, B., Bodea, L., Klaus, C., Ginolhac, A., Halder, R., Sinkkonen, L., Walter, J., Colonna, M., & Neumann, H. (2019) · Glia · doi:10.1002/glia.23563 · Cited by 104
Acute Trem2 reduction triggers increased microglial phagocytosis, slowing amyloid deposition in mice
Schoch, K. M., Ezerskiy, L. A., Morhaus, M. M., Bannon, R. N., Sauerbeck, A. D., Shabsovich, M., Jafar-nejad, P., Rigo, F., & Miller, T. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100356118 · Cited by 78
Brendel, M., Kleinberger, G., Probst, F., Jaworska, A., Overhoff, F., Blume, T., Albert, N. L., Carlsen, J., Lindner, S., Gildehaus, F. J., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00008 · Cited by 66 · cited 1×
“TREM2 expression has been shown to be upregulated in microglia that associate with amyloid plaques in Alzheimer's disease (AD) (Brendel et al., 2017; Giraldo et al., 2013; Jay et al., 2015; Yuan et al., 2016).”
BackgroundHall-Roberts, H., Agarwal, D., Obst, J., Smith, T. B., Monzón-Sandoval, J., Di Daniel, E., Webber, C., James, W. S., Mead, E., Davis, J. B., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00709-z · Cited by 62 · cited 4×
“Hall-Roberts et al. (2020) used hiPSC-derived macrophages, and found no difference in the pSYK response between WT and R47H TREM2 to dead neurons.”
BackgroundMethodResultInfluentialFrontobasal gray matter loss is associated with the TREM2 p.R47H variant
Luis, E. O., Ortega-Cubero, S., Lamet, I., Razquin, C., Cruchaga, C., Benitez, B. A., Lorenzo, E., Irigoyen, J., Pastor, M. A., & Pastor, P. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.007 · Cited by 47 · cited 1×
“In AD and MCI patients, the heterozygous R47H TREM2 variant was associated with substantially increased loss of cortical gray matter (Luis et al., 2014).”
Background
Cited by
Neuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
Self-citationBrown, G. C. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00921-6 · Cited by 129
Self-citationYang, G., Xu, X., Gao, W., Wang, X., Zhao, Y., & Xu, Y. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1700692 · Cited by 85
Penney, J., Ralvenius, W. T., Loon, A., Cerit, O., Dileep, V., Milo, B., Pao, P., Woolf, H., & Tsai, L. (2024) · Glia · doi:10.1002/glia.24485 · Cited by 52
Pocock, J., Vasilopoulou, F., Svensson, E., & Cosker, K. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110020 · Cited by 54
Metadata
- Authors
- Popescu, A. S., Butler, C. A., Allendorf, D. H., Piers, T. M., Mallach, A., Roewe, J., Reinhardt, P., Cinti, A., Redaelli, L., Boudesco, C., Pradier, L., Pocock, J. M., Thornton, P., & Brown, G. C.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2022-12-08
- Volume
- 71
- Issue
- 4
- Pages
- 974-990
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W4310941345
- Cited by
- 49
- References
- 31
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.